Position in GYRE
as of Jun 30, 2026
· filed Aug 12, 2026
Position Value
$111,140
+$19,722 QoQ
Shares Held
16,865
+28.6% QoQ
Ownership
0.015%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#22
of 60 holders
Holding Since
Jun 2024
9 quarters on record
Voting authority
Sole 28%
Shared 0%
None 72%
Common Shares in GYRE Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026RHUMBLINE ADVISERS holds $1,414,750,230 across 329 Biotechnology names. GYRE ranks #273 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
396,380 | $196,893,837 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
157,794 | $98,390,870 | |
| 3 | MRNA |
Moderna, Inc.
|
809,853 | $56,714,005 | |
| 4 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
165,579 | $49,844,246 | |
| 5 | INCY |
Incyte Corp
|
428,533 | $48,578,500 | |
| 6 | RVMD |
Revolution Medicines, Inc.
|
226,008 | $42,326,778 | |
| 7 | ROIV |
Roivant Sciences Ltd.
|
1,178,789 | $41,717,342 | |
| 8 | JAZZ |
Jazz Pharmaceuticals plc
|
163,018 | $39,282,447 |
All Filings in GYRE
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $111,140 | 16,865 | Shares | Sole | 2026-08-12 | |
| 2026-03-31 | $91,418 | 13,116 | Shares | Sole | 2026-05-12 | |
| 2025-12-31 | $99,065 | 14,032 | Shares | Sole | 2026-02-13 | |
| 2025-09-30 | $100,202 | 13,432 | Shares | Sole | 2025-11-06 | |
| 2025-06-30 | $118,967 | 16,186 | Shares | Sole | 2025-08-12 | |
| 2025-03-31 | $86,008 | 11,141 | Shares | Sole | 2025-05-29 | |
| 2024-12-31 | $126,227 | 10,432 | Shares | Sole | 2025-05-29 | |
| 2024-09-30 | $130,716 | 10,424 | Shares | Sole | 2024-11-12 | |
| 2024-06-30 | $122,771 | 10,291 | Shares | Sole | 2024-08-01 | |
| No filing history on record for this holder in this stock. | ||||||